eNauka - pregled

Pregled prema Projekat Argenx

Prikaz rezultata 1 do 8 od 8
GodinaNaslovAutor(i)Tip rezultataMp-kat.
2024Autophagy regulation in peripheral blood mononuclear cells of patients with myasthenia gravisMilošević, Emina  ; Paunović, Verica  ; Stamenković, Marina M.  ; Perić, Stojan  ; Basta, Ivana  ; Božović, Ivo ; Stević, Zorica ; Trajković, Vladimir  Conference Paper
Mp. category will be shown later
2023Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)Sacca, Francesco; Barnett, Carolina; Vu, Tuan; Perić, Stojan Z.  ; Phillips, Glenn A.; Zhao, Sihui; Qi, Cynthia Z.; Gelinas, Deborah; Chiroli, Silvia; Verschuuren, Jan JGMArticle
21aM21a
2022Efgartigimod improved quality-of-life in gMG: a randomised, double-blinded, placebo-controlled, phase 3 trial (ADAPT)Sacca, Francesco; Barnett-Tapia, C.; Vu, T.; Peric, Stojan Z.  ; Phillips, Glenn A.; Zhao, Sihui; Gelinas, D.; Chiroli, Silvia; Verschuuren, J.Konferencijski rad
Mp kategorija će biti prikazana naknadno.
2026European S2k guidelines on management of autoimmune blistering diseases in children and adolescentsNanda, A; ...; Nikolic, M; ...; (broj, koautora 32)Naučni članak
21aM21a - Vodeći međunarodni časopis kategorije M21a
2024Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT plus ): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravisHoward, Jr James F.; ...; Perić, Stojan Z.  ; ...; (broj koautora 17)Naučni članak
21M21 - Vodeći međunarodni časopis kategorije M21
2026Plasma miR-150-5p as a biomarker for immunosuppressive therapy response in acetylcholine receptor positive myasthenia gravis: a long-term prospective longitudinal studyGarai, Nemanja  ; Madić, Sanja  ; Ivanović, Vukan ; Palibrk, Aleksa; Pešović, Jovan  ; Brkušanin, Miloš  ; Basta, Ivana  ; Perić, Stojan  ; Savić-Pavićević, Dušanka  Naučni članak
21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+
2021Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT) : a multicentre, randomised, placebo-controlled, phase 3 trialHoward, James; ...; Perk, Stojan; ...; (broj, koautora 16)Naučni članak
21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+
2024Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE) : a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trialAllen, Jeffrey A; ...; Basta, Ivana Z; ...; (broj, koautora 26)Naučni članak
21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+